Business context and reporting period
Repligen Corporation filed this unaudited Form 10-Q for the quarter and nine months ended September 30, 2016. The company develops, manufactures and sells products used in biopharmaceutical manufacturing, including Protein A ligands, XCell ATF filtration systems and OPUS chromatography columns. It reports as one operating segment. The results include Atoll GmbH, acquired April 1, 2016 and renamed Repligen GmbH in September.
Financial performance and position
Amounts below are in millions of dollars unless stated otherwise.
| Metric | Q3 2016 | Q3 2015 | Nine months 2016 | Nine months 2015 |
|---|---|---|---|---|
| Product revenue | $24.7 | $19.8 | $78.9 | $62.1 |
| Gross margin | 54.4% | 57.4% | 55.7% | 59.6% |
| Operating income | $3.7 | $3.7 | $13.1 | $12.3 |
| Net income | $1.2 | $2.5 | $6.7 | $9.1 |
| Diluted EPS | $0.03 | $0.08 | $0.20 | $0.27 |
| Operating cash flow | — | $5.6 | $11.7 |
- Revenue grew 24.5% in Q3 and 27.1% over nine months, primarily on higher chromatography-column and ATF orders. Management cautioned that order timing, customer development activity and regulatory approvals can cause substantial quarterly fluctuations.
- Gross margin declined as product costs grew faster than revenue; management cited product mix and expected further fourth-quarter variability from production volume and mix. Operating expenses increased 29.8% in Q3 and 32.4% year to date, including higher R&D, commercial and administrative spending, acquisition costs, and contingent-consideration remeasurement.
- Q3 net income fell despite revenue growth, with interest expense from the new notes and acquisition-related contingent-consideration expense among the factors. Nine-month GAAP net income also declined. Non-GAAP adjusted net income was $2.9 million for Q3 ($2.8 million prior year) and $12.6 million for nine months ($11.2 million prior year); these company-defined measures exclude specified acquisition, contingent-consideration and non-cash interest items.
- Cash and marketable securities totaled $178.7 million at September 30, versus $73.4 million at December 31, 2015. Working capital was $199.6 million, up from $84.5 million. Operating cash flow was $5.6 million; capital expenditures were $3.5 million. Cash generation was reduced by increases in receivables and inventory and decreases in payables and accrued liabilities.
- At September 30, the company had $115 million principal of 2.125% convertible senior notes due 2021, carried at $94.3 million after discounts and issuance costs. The notes’ effective interest rate is 6.6%; fair value of principal was approximately $131.8 million. Management said it intended to settle conversions using cash for principal and shares for any excess conversion value.
- Total assets were $285.1 million and stockholders’ equity was $166.5 million. Current assets were $219.8 million and current liabilities $20.2 million. Accrued contingent consideration was $6.3 million.
Material changes, outlook and risks
- The Atoll acquisition had a stated total purchase price of approximately $25.3 million, including $10.2 million cash, $14.1 million in stock and estimated contingent consideration. It added chromatography-column products and a Central European customer-facing presence. The purchase-price allocation remained preliminary. Atoll contributed approximately $1.04 million of Q3 revenue and $45,000 of net income.
- In May, Repligen issued $115 million of convertible notes and received approximately $111.1 million net proceeds. This substantially increased liquidity but introduced debt and material interest expense.
- The company launched its XCell ATF single-use product line during Q3. In October, after the reporting period, it introduced OPUS R columns; the unpacking-port feature for its largest production-scale columns was planned for Q1 2017.
- No quantified revenue or earnings guidance is provided in the supplied filing text. Management expected 2016 operating expenses to increase as it expanded its bioprocessing business and planned continued investment in product development and commercial capabilities. It said existing cash was adequate for foreseeable needs absent additional acquisitions, while noting future strategic transactions could require financing and potentially dilute shareholders.
- Key risks include fluctuating customer orders and product mix, reliance on major customers (GE Healthcare and MilliporeSigma together represented 51% of Q3 revenue), acquisition integration and milestone estimates, foreign-exchange exposure without hedging, and the possibility of needing additional financing on uncertain terms. Management reported no known legal proceedings expected to have a material adverse effect, and no material changes to previously disclosed risk factors other than the financing risk described in this filing.
- Management said disclosure controls were effective. The control assessment excluded Atoll, a recently acquired business, under the SEC’s acquisition-related guidance. The filing reports no other material change to internal control during the period.
Investor verification priorities
- Check subsequent revenue and order trends, particularly whether Q3 growth in chromatography columns and ATF products continued and how customer concentration evolved.
- Track gross margin and operating-cost trends, including the effects of product mix, expansion spending and acquisition-related charges.
- Review operating cash conversion and inventory levels; inventory rose to $24.5 million from $18.0 million at year-end, while nine-month operating cash flow declined from the prior year.
- Verify the final Atoll purchase-price allocation, integration progress and whether its revenue milestones—and the larger Refine contingent payments—are achieved. Q4 forecast changes could materially alter contingent-consideration fair values.
- Assess the convertible notes’ interest burden, conversion and settlement terms, and any financing or dilution implications of future acquisitions.
- Monitor launch and commercialization progress for XCell ATF single-use and OPUS R products, as well as the adoption and financial impact of new accounting standards still under assessment.